Remsleep Holdings INC 10-Q quarterly reports

REMSLEEP HOLDINGS, INC. reported a net loss of $393,410 for the six months ended June 30, 2026, a significant increase from the prior year, alongside a going concern warning.

REMSLEEP Holdings, Inc. reported a significantly wider net loss in Q3 2025, driven by a sharp decline in revenue during its product transition and substantial non-cash compensation expenses.

REMSLEEP Holdings, Inc. reports a significant revenue decline and increased liabilities, raising substantial doubt about its ability to continue as a going concern despite new product sales.

Remsleep Holdings reports a net loss of $85,488 for Q1 2025, shifting focus to the launch of their DeltaWave product while navigating going concern challenges.

REMSleep Holdings reported a net loss of $756,088 for the nine months ended September 30, 2024, with increased development expenses and concerns about the company's ability to continue as a going concern.

REMSleep Holdings experienced a decrease in revenue and increased net loss in the second quarter of 2024, while also achieving FDA approval for its DeltaWave product.

REMSleep Holdings has filed an amended 10-Q report for the quarter ended March 31, 2024, to correct the number of outstanding shares, while also reporting a net loss and ongoing concerns about its ability to continue as a going concern.

REMSleep Holdings, a company focused on sleep apnea solutions, has obtained a $143,000 convertible promissory note while reporting a net loss of $252,580 for the quarter ending March 31, 2024.